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Background. Obesity has emerged as a major cause of di-
abetes, cardiovascular disease, and renal insufficiency world-
wide. Obese Zucker rats exhibit hyperphagia, obesity, insulin
resistance, hyperlipidemia, and glomerulosclerosis and are fre-
quently used as a model to study hereditary form of metabolic
syndrome. Nitric oxide plays a major role in preservation of re-
nal function and structure. The present study was designed to
test the hypothesis that renal disease in this model may be as-
sociated with down-regulation of endothelial (eNOS) and neu-
romal NO synthases (nNOS) in the kidney. The study further
sought to explore expressions of caveolin-1, phospho AKt, and
calmodulin, which regulate activities of constituitive NOS iso-
forms, as well as soluble guanylate cyclase (sGC), which is in-
volved in NO signaling.
Methods. Twenty-two-week-old male obese and lean Zucker
rats were studied. Body weight, serum lipids, urine albumin ex-
cretion, and renal tissue abundance of the above proteins were
determined.
Results. Serum glucose and arterial pressure were unchanged,
whereas urinary NO metabolite (NOv ) excretion and renal tis-
sue nitrotyrosine abundance were markedly reduced (denoting
depressed NO production) in the obese versus lean Zucker rats.
This was accompanied by significant glomerulosclerosis, tubu-
lointerstitial damage, renal immune cell infiltration, marked
down-regulations of renal tissue eNOS and nNOS, mild reduc-
tion of caveolin-1, and unchanged calmodulin, phospho-AKt,
and sGC.
Conclusion. Hereditary obesity can result in down-
regulations of kidney eNOS and nNOS, marked reduction of
NO production, and glomerulosclerosis prior to the onset of
frank diabetes and hypertension.
Obesity has emerged as a major cause of diabetes, re-
nal disease, and cardiovascular complications worldwide.
Pathologic obesity can cause glomerular hypertrophy,
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mesangial expansion, focal segmental glomerulosclero-
sis, and glomerular proteinuria in humans and experi-
mental animals [1–4]. In addition, obesity is associated
with an increased risk of type 2 diabetes, which is the
leading cause of cardiovascular disease and chronic re-
nal failure [5–8]. Various animal models have been em-
ployed to investigate the pathogenesis of nephropathy
associated with obesity and type 2 diabetes [1, 3, 9, 10].
One such model is the obese Zucker rat (fa/fa-rat) [1, 3,
10], in which an autosomal-recessive mutation of the fa-
gene, encoding the leptin receptor, results in hyperphagia,
obesity, hyperlipidemia, peripheral insulin resistance, hy-
perinsulinemia, and impaired glucose tolerance [11, 12].
With increasing age, these rats develop proteinuria and
focal segmental glomerulosclerosis [1, 3, 10, 13].
Nitric oxide (NO) plays a major role in regulation of
arterial pressure as well as renal and cardiovascular func-
tion and structure. Numerous studies have explored NO
production and NO synthase activity in the vascular tis-
sues of the Zucker obese rats [14–22]. However, the avail-
able data on expressions of NO synthase (NOS) isoforms
and proteins involved in regulation of NOS activity and
NO signaling in the kidney of Zucker rats are limited.
Therefore, this study was conducted to explore the ex-
pressions of constitutive isoforms of NOS, as well as key
proteins involved in regulation of their enzymatic activi-
ties (phospho AKt, calmodulin, and caveolin-1) and NO
signaling (soluble guanylate cyclase) in the kidneys of
obese and lean Zucker rats.
METHODS
Animals
Twenty-two-week-old male Zucker obese and lean rats
were used (Harlan Sprague, Inc., Indianapolis, IN, USA).
The animals were housed in a climate-controlled and
light-regulated room (12 hour light/12 hour dark cycle).
Food and water were provided ad libitum. Body weight
and tail arterial pressure (tail plethysmography) were
measured and a 24-hour urine collection was obtained
using metabolic cages. Urine specimens were stored at
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−20◦C until assayed. The animals were then anesthetized
(nembutal, 50 mg/kg, IP) and euthanized by exsanguina-
tions using cardiac puncture between the hours of 10
and 12 AM. The left kidney was immediately removed,
cleaned, snap frozen in liquid nitrogen, and stored at
−70◦C until processed. The remaining kidney was fixed
in 10% formalin and used for histologic and immunohis-
tologic examination.
Tissue preparation
Kidney cortex was separated and homogenized in
10 mmol/L HEPES buffer, pH 7.4, containing 320 nmol/L
sucrose, 1 mmol/L EDTA, 1 mmol/L DTT, 10 mg/mL le-
upeptin, 2 mg/mL aprotinin, and 1 lmol/L phenylmethyl-
sulfonyl fluoride (PMSF) at 0 to 4◦C. Homogenates were
centrifuged at 12,000g for 5 minutes at 4◦C to remove tis-
sue debris and nuclear fragments. The supernatant was
used to perform the Western analyses. Total protein con-
centration was determined with the use of a Bio-Rad kit
(Bio-Rad Laboratories, Hercules, CA, USA).
Western blot analyses
Protein abundance of endothelial NOS (eNOS), neu-
ronal NOS (nNOS), caveolin-1, phospho AKt, calmod-
ulin, and soluble guanylate cyclase (sGC) were measured
by Western blot analysis as described in our earlier stud-
ies [23, 24]. Antibody against B subunit of sGC was
purchased from Calbiochem (San Diego, CA, USA).
Anti-caveolin-1 antibody was purchased from Affinity
Bioreagents, Inc. (Golden, CO, USA). Antibodies to
phospho AKt, eNOS, and nNOS were purchased from
BD Biosciences (San Diego, CA, USA). On each occa-
sion, the Ponceau S staining was used to verify the unifor-
mity of protein load and transfer efficiency across the test
samples. Experiments failing this test were discarded.
Measurements of urine total NO2− plus NO3− (NOv)
The NOv concentration in the urine samples was de-
termined as described earlier [25] using the purge system
of a Sievers Instruments, Inc. (Boulder, CO, USA). In a
typical assay, 10 lL of the sample was injected into the
purge vessel, and all samples were run in triplicates. The
amount of NOv in the sample was determined by inter-
polation of the result in the standard curve.
Histology and immunohistology
Light microscopy studies were performed in formalin-
fixed paraffin embedded kidney sections stained with
periodic acid–Schiff (PAS) and hematoxylin and eosin
(H&E) stainings. All histologic and immunohistologic
studies were done blindly without previous knowledge
of the experimental groups. Severity of glomerulosclero-
sis was evaluated by determining the number of glomeruli
showing sclerosis and the area within the glomerulus
showing sclerosis. At least 32 glomeruli were examined in
each biopsy (range 32–66). As described in previous com-
munications [26–28], the glomeruli were graded from 0
to +4 (Grade 0 = normal, grade 1 = <25% involvement
of the glomerular tuft, grade 2 = 25–50% involvement
of the glomerular tuft, grade 3 = 50–75% and grade 4 =
sclerosis occupying >75% of the glomerular tuft). The
total glomerulosclerosis score was calculated as follows:
[(1× N glomeruli with +1 score) + (2 × N glomeruli
with +2 score) + (3 × N glomeruli with +3 score) + (4 ×
N glomeruli with +4 score)]/total number of glomeruli
examined.
Tubulointerstitial damage (infiltration, fibrosis, tubu-
lar dilatation, or atrophy) was evaluated using a damage
score as described previously [26, 28, 29]. The grading was
done according to the extent of the damaged tubuloint-
erstitial area in the renal cortex (0 = normal, grade +1 =
<10%, grade +2 = 10–25%, grade +3 = 25–50%, grade
+4 = 50–75%, grade +5 = 75–100%). The extent of tubu-
lointerstitial damage was determined in successive fields
examined in the entire cortical and juxtamedullary ar-
eas, suitable for evaluation, in each specimen. Damaged
areas were defined visually in each ×200 field and quan-
tified as a percent of the total area under examination
using computer assisted image analysis (Optimas, Media
Cybernetics, Silver Spring, MD, USA).
Avidin-biotin-peroxidase methodology was used to
identify lymphocytes (CD5 positive cells) and macrop-
hages (ED1 positive cells) as described in previous com-
munications [30]. Cellular infiltration was evaluated sepa-
rately in the glomeruli and in tubulointerstitial areas and
expressed as positive cells per glomerular cross section
(gcs) or positive cells per mm2, respectively.
Antisera
Monoclonal antibodies were used to identify lympho-
cytes (anti-CD5 clone MRCOX19; Biosource, Camarillo,
CA, USA) and macrophages (anti ED1; Harlan Bioprod-
ucts, Indianapolis, IN, USA). Secondary rat anti-mouse
and donkey anti-rabbit antibodies with minimal cross-
reactivity to rat serum proteins were obtained from Ac-
curate Chemical and Scientific Co. (Westbury, NY, USA).
Miscellaneous tests
Urinary albumin and creatinine concentrations were
measured using Nephrat kit and Creatinine Compan-
ion kit purchased from Exocell, Inc. (Philadelphia, PA,
USA). Plasma glucose was measured using Beckman glu-
cose analyzer (Beckman Coulter, Fullerton, CA, USA).
Serum cholesterol, triglyceride, and creatinine were de-
termined by AnTech Diagnostics (Irvine, CA, USA).
Data presentation and analysis
Data are presented as mean ± SEM. Student t test was
used in statistical evaluation of the data. P values ≤ 0.05
were considered significant.
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Table 1. Body weight, blood pressure, plasma lipid, albumin,
creatinine, and random plasma glucose levels
Lean Obese
Body weight g 423 ± 8 688 ± 11c
Serum cholesterol mg/dL 79 ± 6 164 ± 13c
Serum triglyceride mg/dL 87 ± 18 549 ± 106b
Urinary albumin excretion mg/day 6 ± 3 15 ± 2a
Serum creatinine mg/dL 0.30 ± 0.04 0.3 ± 0.1a
Blood pressure mm Hg 145 ± 10 131 ± 8
Random plasma glucose mg/dL 218 ± 14 277 ± 54
aP < 0.05; bP < 0.01; cP < 0.001. N = 6 in each group
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Fig. 1. Urinary NOv excretion (upper panel) and representative West-
ern blots and group data depicting nitrotyrosine abundance in the kid-
ney cortex (lower panel) of obese and lean Zucker rats. N = 6 in each
group, ∗P < 0.05.
RESULTS
General data
Data are summarized in Table 1. As expected, body
weight in the obese Zucker rats was significantly greater
than in the lean Zucker rats. Obese Zucker rats exhib-
ited elevated urinary albumin excretion, confirming ear-
lier studies [1, 10, 13, 29]. Likewise, serum cholesterol and
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Fig. 2. Representative Western blots and group data depicting eNOS
and nNOS protein abundance in the kidney cortex of the obese and
lean Zucker rats. N = 6 in each group, ∗P < 0.05.
triglyceride concentrations were significantly elevated in
the in the obese Zucker rats as compared to the lean
controls. However, arterial pressure and serum glucose
concentrations were not significantly different among the
two groups.
NOS, nitrotyrosine, and urinary NOv data
Data are depicted in Figures 1 and 2. The eNOS abun-
dance in the renal cortex was significantly lower in the
obese Zucker rats compared to that found in the lean
Zucker rats. Similarly, nNOS protein abundance in the
renal cortex was significantly lower in the obese Zucker
rats than in the lean Zucker rats. The reduction of renal
tissue eNOS and nNOS protein abundance in the obese
Zucker rats was accompanied by a significant reduction of
tissue nitrotyrosine abundance and urinary NOv excre-
tion, pointing to reduced NO production in these animals.
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Fig. 3. Representative Western blots and group data depicting pro-
tein abundance of caveolin-1, phospho-AKt, and calmodulin in the
kidney cortex of obese and lean Zucker rats. N = 6 in each group,
∗P < 0.05.
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Fig. 4. Representative Western blot and group data depicting soluble
guanylate cyclase (sGC) protein abundance in the kidney cortex of the
obese and lean Zucker rats. N = 6 in each group, no differences found.
Tissue, caveolin-1, calmodulin, phospho-AKt,
and sGC data
Data are shown in Figures 3 and 4. There was no signif-
icant difference in calmodulin protein abundance in the
kidney cortex (Fig. 6) among the obese and lean Zucker
rats. Likewise, no significant difference was found in ei-
ther phospho-AKt or sGC protein abundance in the kid-
ney cortex among the obese and lean Zucker rats. In
contrast, caveolin-1 abundance was significantly lower in
the obese than in the lean Zucker rats.
Histology and immunohistology
Data are illustrated in Figure 5A to F. Glomerular
and tubulointerstitial damage scores were significantly
higher in the obese Zucker rats than in the lean Zucker
rats, which had essentially normal histology. Glomerular
macrophage and lymphocyte infiltration (CD5-positive
cells) were significantly increased in the glomeruli and
tubulointerstitial regions in the obese Zucker rats.
DISCUSSION
Compared to the lean Zucker rats, obese Zucker rats
employed in the present study showed significant in-
creases in body weight, serum cholesterol, and triglyc-
eride levels at 22 weeks of age. However, at this stage,
arterial blood pressure and serum glucose concentration
in the obese Zucker rats were not significantly different
from the corresponding values found in the lean Zucker
rats.
Despite absence of frank diabetes and hypertension,
our obese Zucker rats exhibited significant albuminuria,
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Fig. 5. Glomerular and tubulointerstitial damage scores (A), and glomerular (B) and tubulointerstitial (C) infiltration of lymphocytes (CD5 positive
cells) and macrophages (ED1 positive cells). Values in obese Zucker rats (closed columns) are contrasted with those in the lean Zucker rats (open
columns). ∗P < 0.05, ∗∗P < 0.05, ∗∗∗P < 0.001. Microphotographs that illustrate an essentially normal appearance in the lean Zucker rats (D) and
various abnormalities in obese Zucker rats including focal glomerulosclerosis (arrow) in a glomerulus surrounded by some dilated tubules (E), and
tubulointerstitial injury (F) characterized by focal cellular infiltration (arrow heads) and tubules showing intraluminal lipid droplets (asterisks), as
well as intracellular vacuolization (arrows) (all microphotographs are PAS staining, original magnification ×400). Also known are the macrophage
(ED-1) infiltration scores in the kidney cortex of the obese and lean Zucker rats.
confirming the occurrence of kidney disease. This obser-
vation is consistent with the results of the earlier studies
in this model [1, 3, 10, 13, 29]. The presence of albumin-
uria was accompanied by significant glomerulosclerosis
in the 22-week-old obese Zucker rats.
Previous studies have demonstrated that mono-
cyte/macrophage influx precedes the development of
glomerulosclerosis in the obese Zucker rat [31]. The
findings of the present study confirm the occurrence
of glomerulosclerosis and tubulointerstitial damage,
as well as glomerular and tubulointerstitial infiltra-
tion of immune cells in the obese Zucker rats. Since
macrophages/monocytes play a role in the pathogen-
esis of focal and diffuse glomerulosclerosis in chronic
nephropathies of various etiologies [32], it is likely that
they are also involved in the pathogenesis of nephropathy
in the obese Zucker rat.
NO plays a major role in the regulation of vascular re-
sistance and regional and systemic hemodynamics. NO
generated by different NOS isoforms in the kidney con-
tributes to the regulation of renal vascular resistance,
renal blood flow, glomerular filtration rate, and renin se-
cretion [33–37]. In addition, NO promotes sodium excre-
tion directly by suppressing tubular sodium reabsorption
and indirectly by modulating renal medullary blood flow
[38, 39]. Besides its critical role in regulation of renal
and vascular functions, NO serves as a potent inhibitor
of platelet activation, cell adhesion, proliferation, and
matrix accumulation. Consequently, a reduction in NO
bioavailability can contribute to inflammation, cell pro-
liferation, and matrix expansion.
The presence of glomerulosclerosis and albuminuria in
the 22-week-old obese Zucker rats was accompanied by
significant reductions of eNOS and nNOS abundance in
the kidney cortex. The observed down-regulation of NOS
isotypes in the renal cortex was accompanied by a signif-
icant reduction of urinary excretion of NO metabolites
(NOv ) and tissue nitrotyrosine abundance. Together, the
reduction in urinary excretion of NOv and renal tissue
abundance of nitrotyrosine point to diminished NO pro-
duction in the obese Zucker rats and, as such, provides
functional evidence for the observed down-regulation of
NOS isoforms in this model.
Activation of eNOS and nNOS is dependent on
calcium-mediated binding of calmodulin to the inac-
tive enzyme. Moreover, eNOS activity is inhibited by its
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binding to caveolin-1 and markedly amplified by phospho
AKt-catalyzed phosphorylation of the enzyme [40]. In an
attempt to further explore the mechanism(s) responsi-
ble for diminished NO production in obese Zucker rats,
we determined the abundance of these important NOS-
regulatory proteins as well. The study revealed a signif-
icant reduction of caveolin-1 and no significant change
in the abundance of either calmodulin or phospho-AKt
in the obese Zucker rats, thus excluding dysregulation
of these proteins as a possible cause of diminished NO
production in these animals.
Activation of soluble guanylate cyclase by NO results
in generation of cGMP, which mediates many of the bi-
ological actions of NO. We therefore sought to explore
the possible effect of obesity on the abundance of this
key enzyme in the kidneys of the study animals. The re-
sults showed no significant difference in the abundance
of soluble guanylate cyclase between the obese and lean
Zucker rats.
Recent studies have revealed significant down-
regulation of kidney NOS isotypes and diminished NO
availability in the genetically normal rats with diet-
induced obesity and metabolic syndrome without frank
diabetes [41]. It thus appears that both genetic and diet-
induced obesity can diminish NO availability that is ac-
companied by, and partly due to, down-regulation of NOS
isotypes in the kidney. It is of note that proteinuria in rats
with puromycin-induced glomerular proteinuria results
in down-regulation of nNOS expression in the kidney
[42]. Thus, the obesity-associated proteinuria may play a
part in the development of nNOS deficiency in this model.
In addition, diabetes and simulated hyperglycemia have
been shown to down-regulate eNOS in vivo and in vitro,
respectively [43, 44]. However, animals employed in the
present study did not have frank diabetes. Finally, hy-
perlipidemia is known to cause endothelial dysfunction
and limit NO availability. Therefore, presence of se-
vere hyperlipidemia in the obese Zucker rats may have
contributed to the observed down-regulations of NOS
isotypes.
CONCLUSION
Taken together, these observations suggest that obesity
and hyperlipidemia in the absence of frank diabetes and
hypertension can lead to down-regulation of renal tissue
eNOS and nNOS, as well as significant glomerulosclerosis
and albuminuria in this model.
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